Attracted by positive Phase II results for the company’s lead antifibrotic antisense drug candidate EXC 001, Pfizer has bought privately held Excaliard Pharmaceuticals, a spin-off of Isis Pharmaceuticals, for an undisclosed sum. EXC 011, which is being developed for the treatment of excessive skin scarring, was co-discovered by Excaliard and Isis.